Literature DB >> 36044050

A ray of hope in the discord: is adding piperacillin-tazobactam to vancomycin truly more nephrotoxic?

Jean-Maxime Côté1,2, Sandra L Kane-Gill3,4, Patrick T Murray5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36044050     DOI： 10.1007/s00134-022-06861-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   41.787


× No keyword cloud information.
  7 in total

1.  Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.

Authors:  Kathryn M Cook; Jessica Gillon; Alison G Grisso; Ritu Banerjee; Natalia Jimenez-Truque; Elizabeth J Phillips; Sara L Van Driest
Journal:  J Pediatric Infect Dis Soc       Date:  2019-07-01       Impact factor: 3.164

2.  Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.

Authors:  Adam M Blevins; Jennifer N Lashinsky; Craig McCammon; Marin Kollef; Scott Micek; Paul Juang
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin-Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study.

Authors:  Sandra L Kane-Gill; Marlies Ostermann; Jing Shi; Emily L Joyce; John A Kellum
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

4.  Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.

Authors:  Mitchell S Buckley; Ivan A Komerdelj; Paul A D'Alessio; Pooja Rangan; Sumit K Agarwal; Nicole C Tinta; Brandon K Martinez; Delia S Ziadat; Melanie J Yerondopoulos; Emir Kobic; Sandra L Kane-Gill
Journal:  J Crit Care       Date:  2021-11-09       Impact factor: 3.425

5.  Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.

Authors:  Diana J Schreier; Kianoush B Kashani; Ankit Sakhuja; Kristin C Mara; Mohammad S Tootooni; Heather A Personett; Sarah Nelson; Andrew D Rule; James M Steckelberg; Aaron J Tande; Erin F Barreto
Journal:  Clin Infect Dis       Date:  2019-04-24       Impact factor: 9.079

6.  Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.

Authors:  Nuala J Meyer; Michael G S Shashaty; Todd A Miano; Sean Hennessy; Wei Yang; Thomas G Dunn; Ariel R Weisman; Oluwatosin Oniyide; Roseline S Agyekum; Alexandra P Turner; Caroline A G Ittner; Brian J Anderson; F Perry Wilson; Raymond Townsend; John P Reilly; Heather M Giannini; Christopher V Cosgriff; Tiffanie K Jones
Journal:  Intensive Care Med       Date:  2022-07-14       Impact factor: 41.787

7.  Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017.

Authors:  Jean-Louis Vincent; Yasser Sakr; Mervyn Singer; Ignacio Martin-Loeches; Flavia R Machado; John C Marshall; Simon Finfer; Paolo Pelosi; Luca Brazzi; Dita Aditianingsih; Jean-François Timsit; Bin Du; Xavier Wittebole; Jan Máca; Santhana Kannan; Luis A Gorordo-Delsol; Jan J De Waele; Yatin Mehta; Marc J M Bonten; Ashish K Khanna; Marin Kollef; Mariesa Human; Derek C Angus
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.